Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Dec;62(12):1168–1177. doi: 10.1136/ard.2003.009563

Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

L B A van de Putte 1, R Rau 1, F Breedveld 1, J Kalden 1, M Malaise 1, P L C M van Riel 1, M Schattenkirchner 1, P Emery 1, G Burmester 1, H Zeidler 1, H Moutsopoulos 1, K Beck 1, H Kupper 1
PMCID: PMC1754401  PMID: 14644854

Abstract

Objectives: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA).

Methods: During a 12 week, double blind, placebo controlled study, 284 patients were randomly allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs.

Results: Adalimumab significantly improved the signs and symptoms of RA for all efficacy measures. ACR20 responses with adalimumab were significant at each assessment versus placebo (p⩽0.01). Additionally, ACR responses with adalimumab were achieved more rapidly than with placebo, with 82/115 (71%) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2. At week 12, for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50.7%, 57.1%, and 54.2%, respectively, versus 10.0% for placebo (p⩽0.001 for all comparisons); ACR50 rates were 23.9%, 27.1%, and 19.4%, respectively, versus 1.4% for placebo (p⩽0.001 for all comparisons); and ACR70 rates were 11.3%, 10.0%, and 8.3%, respectively, versus 0.0% for placebo (p⩽0.05 for all comparisons). All adalimumab doses significantly improved all ACR core criteria at all assessments. The 40 mg and 80 mg doses provided similar benefit. Adalimumab at all doses was generally well tolerated, with only mild or moderate adverse events. Completion rates were 87% for adalimumab and 67% for placebo.

Conclusions: Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose limiting side effects.

Full Text

The Full Text of this article is available as a PDF (595.6 KB).

Figure 1 .

Figure 1

Open in a new tab

Disposition of patients.

Figure 2 .

Figure 2

Open in a new tab

Time course of American College of Rheumatology responses. (A) ACR20 response; (B) ACR50 response; (C) ACR70 response. Student's paired t test for paired observations: *p = 0.01 v baseline; †p = 0.01 v baseline; ‡p = 0.05 v v baseline.

Figure 3 .

Figure 3

Open in a new tab

Improvement in American College of Rheumatology core criteria at 12 weeks with adalimumab 40 mg. Student's t test for paired observations: p = 0.001 v baseline.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antoni C., Kalden J. R. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999 Nov-Dec;17(6 Suppl 18):S73–S77. [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Barrera P., Joosten L. A., den Broeder A. A., van de Putte L. B., van Riel P. L., van den Berg W. B. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 Jul;60(7):660–669. doi: 10.1136/ard.60.7.660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  5. Blumberg S. N., Fox D. A. Rheumatoid arthritis: guidelines for emerging therapies. Am J Manag Care. 2001 Jun;7(6):617–626. [PubMed] [Google Scholar]
  6. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  7. Feldmann M., Brennan F. M., Maini R. N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. doi: 10.1146/annurev.immunol.14.1.397. [DOI] [PubMed] [Google Scholar]
  8. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  9. Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
  10. Fries J. F., Spitz P. W., Young D. Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982 Sep-Oct;9(5):789–793. [PubMed] [Google Scholar]
  11. Goldenberg M. M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999 Jan;21(1):75–2. doi: 10.1016/S0149-2918(00)88269-7. [DOI] [PubMed] [Google Scholar]
  12. Jerne N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 Jan;125C(1-2):373–389. [PubMed] [Google Scholar]
  13. Jespers L. S., Roberts A., Mahler S. M., Winter G., Hoogenboom H. R. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) 1994 Sep;12(9):899–903. doi: 10.1038/nbt0994-899. [DOI] [PubMed] [Google Scholar]
  14. Keysser M., Keysser C., Keitel W., Keysser G. Loss of functional capacity caused by a delayed onset of DMARD therapy in rheumatoid arthritis. Long-term follow-up results of the Keitel function test. Brief definite report. Z Rheumatol. 2001 Apr;60(2):69–73. doi: 10.1007/s003930170076. [DOI] [PubMed] [Google Scholar]
  15. Koopman W. J. Prospects for autoimmune disease: Research advances in rheumatoid arthritis. JAMA. 2001 Feb 7;285(5):648–650. doi: 10.1001/jama.285.5.648. [DOI] [PubMed] [Google Scholar]
  16. Kremer J. M., Lee J. K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 1986 Jul;29(7):822–831. doi: 10.1002/art.1780290702. [DOI] [PubMed] [Google Scholar]
  17. Laiho K., Tuomilehto J., Tilvis R. Prevalence of rheumatoid arthritis and musculoskeletal diseases in the elderly population. Rheumatol Int. 2001 Apr;20(3):85–87. doi: 10.1007/s002960000087. [DOI] [PubMed] [Google Scholar]
  18. Lee D. M., Weinblatt M. E. Rheumatoid arthritis. Lancet. 2001 Sep 15;358(9285):903–911. doi: 10.1016/S0140-6736(01)06075-5. [DOI] [PubMed] [Google Scholar]
  19. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  20. López-Méndez A., Daniel W. W., Reading J. C., Ward J. R., Alarcón G. S. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum. 1993 Oct;36(10):1364–1369. doi: 10.1002/art.1780361006. [DOI] [PubMed] [Google Scholar]
  21. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  22. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  23. O'Dell J. R. How is it best to treat early rheumatoid arthritis patients? Best Pract Res Clin Rheumatol. 2001 Mar;15(1):125–137. doi: 10.1053/berh.2000.0130. [DOI] [PubMed] [Google Scholar]
  24. O'Dell James R., Leff Robert, Paulsen Gail, Haire Claire, Mallek Jack, Eckhoff P. James, Fernandez Ana, Blakely Kent, Wees Steven, Stoner Julie. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 May;46(5):1164–1170. doi: 10.1002/art.10228. [DOI] [PubMed] [Google Scholar]
  25. Park Y. B., Lee S. K., Lee W. K., Suh C. H., Lee C. W., Lee C. H., Song C. H., Lee J. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999 Aug;26(8):1701–1704. [PubMed] [Google Scholar]
  26. Park Yong-Beom, Choi Hyon K., Kim Min-Young, Lee Won-Ki, Song Jungsik, Kim Dong-Kee, Lee Soo-Kon. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med. 2002 Aug 15;113(3):188–193. doi: 10.1016/s0002-9343(02)01186-5. [DOI] [PubMed] [Google Scholar]
  27. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000 Dec;39 (Suppl 2):3–12. doi: 10.1093/rheumatology/39.suppl_2.3. [DOI] [PubMed] [Google Scholar]
  28. Santora L. C., Kaymakcalan Z., Sakorafas P., Krull I. S., Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem. 2001 Dec 15;299(2):119–129. doi: 10.1006/abio.2001.5380. [DOI] [PubMed] [Google Scholar]
  29. Santora L. C., Krull I. S., Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem. 1999 Nov 1;275(1):98–108. doi: 10.1006/abio.1999.4275. [DOI] [PubMed] [Google Scholar]
  30. Scott D. L., Symmons D. P., Coulton B. L., Popert A. J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987 May 16;1(8542):1108–1111. doi: 10.1016/s0140-6736(87)91672-2. [DOI] [PubMed] [Google Scholar]
  31. Silman A., Harrison B., Barrett E., Symmons D. The existence of geographical clusters of cases of inflammatory polyarthritis in a primary care based register. Ann Rheum Dis. 2000 Feb;59(2):152–154. doi: 10.1136/ard.59.2.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Svenson K. L., Lithell H., Hällgren R., Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med. 1987 Nov;147(11):1917–1920. [PubMed] [Google Scholar]
  33. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  34. Weinblatt M. E., Polisson R., Blotner S. D., Sosman J. L., Aliabadi P., Baker N., Weissman B. N. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum. 1993 May;36(5):613–619. doi: 10.1002/art.1780360507. [DOI] [PubMed] [Google Scholar]
  35. den Broeder A. A., Joosten L. A. B., Saxne T., Heinegård D., Fenner H., Miltenburg A. M. M., Frasa W. L. H., van Tits L. J., Buurman W. A., van Riel P. L. C. M. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis. 2002 Apr;61(4):311–318. doi: 10.1136/ard.61.4.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. den Broeder Alfons, van de Putte Leo, Rau Rolf, Schattenkirchner Manfred, Van Riel Piet, Sander Oliver, Binder Christina, Fenner Helmut, Bankmann Yvonne, Velagapudi Raja. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002 Nov;29(11):2288–2298. [PubMed] [Google Scholar]
  37. van Riel P. L., Haagsma C. J., Furst D. E. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol. 1999 Dec;13(4):689–700. doi: 10.1053/berh.1999.0054. [DOI] [PubMed] [Google Scholar]
  38. van der Heijde D. M., van Leeuwen M. A., van Riel P. L., Koster A. M., van 't Hof M. A., van Rijswijk M. H., van de Putte L. B. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992 Jan;35(1):26–34. doi: 10.1002/art.1780350105. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES